A strength of our study design involves using two murine models of pulmonary fibrosis for assessing the protective effects of SPHK1 inhibition: (1) bleomycin (spontaneously resolves) and (2) asbestos (nonresolving) [29,34]. This evidence concerns the gene SPHK1 and pulmonary fibrosis.